DRISCOLL WILLIAM LINDEKE 4
Research Summary
AI-generated summary
POTLATCHDELTIC (PCH) Director William Driscoll Sells Shares
What Happened
- William Lindeke Driscoll, a director of PotlatchDeltic Corp (PCH), reported dispositions of PCH equity on Jan 30, 2026. The filing shows three dispositions to the issuer totaling 340,469.389 PCH shares (124,010.814; 187,884; and 28,574.575 — the last is a derivative unit).
- No per‑share trade price is reported (N/A) because the dispositions occurred at the Effective Time of a Merger. Under the Merger Agreement, each PCH share converted into 1.8185 Rayonier common shares plus $0.61 in cash. The 340,469.389 PCH shares therefore converted into approximately 619,144 Rayonier shares and roughly $207,686 in cash (before any fractional‑share adjustment and rounding).
- This was a disposition tied to the merger (corporate transaction), not an open‑market sale — generally routine in M&A contexts.
Key Details
- Transaction date: January 30, 2026. Form 4 filed February 2, 2026 (within the required filing window).
- Transaction codes: D = disposition to the issuer; one line reported as a derivative disposition (28,574.575 shares).
- Price: N/A (conversion under merger terms). Consideration: 1.8185 Rayonier shares + $0.61 cash per PCH share (per footnote).
- Shares owned after the transaction (as reported): 182,286 shares held in trust; 5,231 shares held as manager; 367 shares as a right to substitute; 187,517 of these shares are expressly disclaimed (see footnote F4).
- Footnotes: F1–F3 explain the merger conversion into Rayonier common shares and conversion of RSUs/stock equivalent units into Rayonier awards or units.
Context
- These dispositions are merger‑related conversions (not voluntary open‑market sales), so they reflect the mechanics of the PotlatchDeltic–Rayonier merger rather than a trading decision by the director.
- Derivative units converted to Rayonier RSU/stock equivalent units per the merger terms; check the issuer’s proxy/merger materials for full details on post‑closing treatment and any vesting or settlement terms.